A H Smelt - JoVE Visualize

Showing results (41-50 of 49) with videos related to

Pageof 5

Sort By:

You have reached the last page of results.This site can display upto 49 results.

The Journal of Clinical Investigation|September 1, 1994

Variable expression of familial dysbetalipoproteinemia in apolipoprotein E*2 (Lys146-->Gln) Allele carriersP de Knijff, A M van den Maagdenberg, D I Boomsma, et al.

Clinical Chemistry|August 1, 1994

Plasma lipoprotein profiles of normocholesterolemic and hypercholesterolemic homozygotes for apolipoprotein E2(Arg158-->Cys) comparedS P Zhao, A H Smelt, A M Van den Maagdenberg, et al.

American Journal of Human Genetics|May 1, 1993

Characterization of five new mutants in the carboxyl-terminal domain of human apolipoprotein E: no cosegregation with severe hyperlipidemiaA M van den Maagdenberg, W Weng, I H de Bruijn, et al.

Arteriosclerosis, Thrombosis, and Vascular Biology|November 14, 2000

Normal oxidative stress and enhanced lipoprotein resistance to in vitro oxidation in hypertriglyceridemia: effects of bezafibrate therapyF H de Man, I J Jonkers, E Schwedhelm, et al.

Atherosclerosis|October 25, 1996

Effect of apolipoprotein E and insulin resistance on VLDL particles in combined hyperlipidemic patientsE J Sijbrands, R G Westendorp, M J Hoffer, et al.

Clinical Science (London, England : 1979)|March 1, 1994

Lipoprotein profiles in a family with two mutants of apolipoprotein E: possible association with hypertriglyceridaemia but not with dysbetalipoproteinaemiaS P Zhao, A M Van den Maagdenberg, T F Vroom, et al.

Arteriosclerosis, Thrombosis, and Vascular Biology|July 15, 2000

Apolipoprotein E2 (Lys146-->Gln) causes hypertriglyceridemia due to an apolipoprotein E variant-specific inhibition of lipolysis of very low density lipoproteins-triglyceridesF de Beer, K W van Dijk, M C Jong, et al.

Atherosclerosis|February 13, 2001

The hypolipidemic action of bezafibrate therapy in hypertriglyceridemia is mediated by upregulation of lipoprotein lipase: no effects on VLDL substrate affinity to lipolysis or LDL receptor bindingF H de Man, F de Beer, A van der Laarse, et al.

Arteriosclerosis and Thrombosis : a Journal of Vascular Biology|November 1, 1994

Plasma lipoproteins in familial dysbetalipoproteinemia associated with apolipoproteins E2(Arg158-->Cys), E3-Leiden, and E2(Lys146-->Gln), and effects of treatment with simvastatinS P Zhao, A H Smelt, A M Van den Maagdenberg, et al.

Pageof 5

Showing results (41-50 of 49) with videos related to

Sort By:

Pageof 5

You have reached the last page of results.This site can display upto 49 results.

The Journal of Clinical Investigation|September 1, 1994

Variable expression of familial dysbetalipoproteinemia in apolipoprotein E*2 (Lys146-->Gln) Allele carriersP de Knijff, A M van den Maagdenberg, D I Boomsma, et al.

Clinical Chemistry|August 1, 1994

Plasma lipoprotein profiles of normocholesterolemic and hypercholesterolemic homozygotes for apolipoprotein E2(Arg158-->Cys) comparedS P Zhao, A H Smelt, A M Van den Maagdenberg, et al.

American Journal of Human Genetics|May 1, 1993

Characterization of five new mutants in the carboxyl-terminal domain of human apolipoprotein E: no cosegregation with severe hyperlipidemiaA M van den Maagdenberg, W Weng, I H de Bruijn, et al.

Arteriosclerosis, Thrombosis, and Vascular Biology|November 14, 2000

Normal oxidative stress and enhanced lipoprotein resistance to in vitro oxidation in hypertriglyceridemia: effects of bezafibrate therapyF H de Man, I J Jonkers, E Schwedhelm, et al.

Atherosclerosis|October 25, 1996

Effect of apolipoprotein E and insulin resistance on VLDL particles in combined hyperlipidemic patientsE J Sijbrands, R G Westendorp, M J Hoffer, et al.

Clinical Science (London, England : 1979)|March 1, 1994

Lipoprotein profiles in a family with two mutants of apolipoprotein E: possible association with hypertriglyceridaemia but not with dysbetalipoproteinaemiaS P Zhao, A M Van den Maagdenberg, T F Vroom, et al.

Arteriosclerosis, Thrombosis, and Vascular Biology|July 15, 2000

Apolipoprotein E2 (Lys146-->Gln) causes hypertriglyceridemia due to an apolipoprotein E variant-specific inhibition of lipolysis of very low density lipoproteins-triglyceridesF de Beer, K W van Dijk, M C Jong, et al.

Atherosclerosis|February 13, 2001

The hypolipidemic action of bezafibrate therapy in hypertriglyceridemia is mediated by upregulation of lipoprotein lipase: no effects on VLDL substrate affinity to lipolysis or LDL receptor bindingF H de Man, F de Beer, A van der Laarse, et al.

Arteriosclerosis and Thrombosis : a Journal of Vascular Biology|November 1, 1994

Plasma lipoproteins in familial dysbetalipoproteinemia associated with apolipoproteins E2(Arg158-->Cys), E3-Leiden, and E2(Lys146-->Gln), and effects of treatment with simvastatinS P Zhao, A H Smelt, A M Van den Maagdenberg, et al.

Pageof 5